The Oncology Institute, Inc.（STLN）财务数据STLNThe Oncology Institute, Inc.

Evaluating the bottom line, Starling Oncology, Inc. maintains a gross margin of 15.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.86%, while the net margin is -6.07%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively STLN converts its operational activities into shareholder value.

In the context of the broader market, STLN competes directly with industry leaders such as DNA and GMRS. With a market capitalization of $658.38M, it holds a significant position in the sector. When comparing efficiency, STLN's gross margin of 15.70% stands against DNA's 91.47% and GMRS's 85.68%. Such benchmarking helps identify whether Starling Oncology, Inc. is trading at a premium or discount relative to its financial performance.

Starling Oncology has shown increasing total revenue, reaching $161,282,000 in Q2 2026, up from $100,267,000 in Q4 2024. The gross margin has also improved, reaching 15.70% in Q2 2026, up from 12.89% in Q4 2024, indicating better operational efficiency.